For patients with lupus nephritis who have responded to induction therapy, mycophenolate mofetil (CellCept) is superior to azathioprine (Azasan) in maintaining a renal response to treatment and in preventing relapse, according to a recent study...
By Wayne Kuznar

The US healthcare and payment delivery model is in transition toward shifting from a volume-based fee-for-service (FFS) model to a performance-based model, with clinicians assuming more risk.

Inflammatory arthritis is characterized by pain, stiffness, loss of function, and impaired quality of life. For patients with inflammatory arthritis, pain management is an important aspect of their care.
The National Human Genome Research Institute (NHGRI), part of the National Institutes of Health (NIH), has awarded $10.5 million to 10 researchers to develop technologies that will assist research on millions of genomic elements that play a role in determining what genes are expressed, and at what levels in different cells. This has particular implications for cancer therapies.
By Sy Schlager, MD, PhD The effective use of biologic disease-modifying antirheumatic drugs (DMARDs) has dramatically improved the treatment of rheumatoid arthritis (RA) over recent years.
Because RA is a chronic, disabling disease that if not properly treated can result in increased direct and indirect costs to the healthcare system, failure to adhere to evidence-based guidelines may negatively impact the value proposition in providing care to these patients.
By Sy Schlager, MD, PhD Gout flares occurring during the early months of urate-lowering therapy are thought to result from the release of urate crystals from deposits softened by the treatment.
By Wayne Kuznar Routine screening for replicating JC polyomavirus (JCPyV) or serum antibodies does not seem to be warranted in rheumatic patients treated with rituximab (Rituxan).
Tight control of rheumatoid arthritis (RA) disease activity is emerging as the new standard of care, and the Rheumatoid Arthritis Disease Activity Measures Working Group (RADAM-WG) of the American College of Rheuma­tology (ACR) now recommends 6 disease activity measures for use in routine clinical practice. The recommendations were coauthored by Jaclyn Anderson, DO, MS, Medical Director at Abbott Labora­tories, Abbott Park, IL.
By Wayne Kuznar Patients who initiate treatment with tumor necrosis factor (TNF) inhibitors for autoimmune diseases are not as likely to develop serious infections as those who start treatment with nonbiologic drugs, according to a study presented at the 2011 American College of Rheumatology meeting.
Page 2 of 3
Results 11 - 20 of 23
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology